MAPT and Alzheimer disease: Disruptions in insulin signaling that regulate the GSK-3β pathway in diabetes, combined with hyperglycemia, may trigger tau phosphorylation and subsequent cleavage, which increases the risk of cognitive disorders, such as Alzheimer’s disease, in diabetic patients (Wee et al., 2023).